Analytical Data
-
Gene name
CD300LB
- Application
-
Alternative Names
CD300LB；CD300B；CLM7；CMRF35A2；CMRF35-like molecule 7
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
A8K4G0
-
Expression Region
1-151aa
-
AA Sequence
MWLPPALLLL SLSGCFSIQG PESVRAPEQG SLTVQCHYKQ GWETYIKWWC RGVRWDTCKI LIETRGSEQG EKSDRVSIKD NQKDRTFTVT MEGLRRDDAD VYWCGIERRG PDLGTQVKVI VDPEGAASTT ASSPTNSNMA VFIGSHKRNH Y
-
Molecular Weight
42 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD300LB is a member of the CD300 family of coupled receptors that is predominantly expressed on immune cells, including monocytes and dendritic cells. Its role in immune regulation has garnered significant interest due to its potential impact on inflammatory responses and autoimmune diseases. CD300LB functions as an inhibitory receptor, modulating the activation and differentiation of immune cells upon engagement with its ligands, which include phosphatidylserine and other negatively charged phospholipids. Recent studies have indicated that CD300LB might play a critical role in maintaining immune homeostasis and self-tolerance, particularly in the context of resolving inflammation and preventing excessive immune activation. Moreover, its involvement in various pathological conditions, such as chronic inflammation and cancer, highlights the importance of studying CD300LB as a potential therapeutic target. The generation of recombinant CD300LB protein facilitates in-depth investigations into its structural and functional properties, allowing researchers to explore its signaling pathways, interaction with ligands, and overall contribution to immune system regulation. Understanding the functional mechanisms of CD300LB may lead to novel strategies for modulating immune responses in diseases characterized by dysregulated immunity. The ongoing research into CD300LB and its recombinant forms continues to advance our knowledge of immune checkpoints and may pave the way for innovative treatments in immunotherapy and beyond.
